With existing clinical data on Polmacoxib limited to only two previous studies, this prospective, multicenter, open-label observational study contributes meaningful real-world insights by examining its effectiveness, onset of action, and safety and tolerability over an eight-week period in everyday Indian clinical practice
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein in human gastric juice
That number could increase significantly over time as supply shortages of the drug are resolved, as indications for the drugs expand, and especially if health-insurance companies increase coverage for the drugs.
Triglycerides are the lipid parameter most responsive to GLP-1 therapy because these drugs reduce liver fat and the liver is where triglyceride-rich particles are assembled
Metabolic rate is lower in this group, so caloric deficit management requires more attention